Onzigolide

Modify Date: 2025-08-24 16:50:24

Onzigolide structure	Common Name	Onzigolide
	CAS Number	778630-77-6	Molecular Weight	1694.20
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₈₆H₁₁₆N₁₆O₁₂S₄	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Onzigolide

Onzigolide (BIM-23A760), a chimeric dopamine-somatostatin compound, shows potent agonist activity at both DA type 2 (D2R) and SST type 2 (SSTR2) receptors[1][2].

Name	Onzigolide

Description	Onzigolide (BIM-23A760), a chimeric dopamine-somatostatin compound, shows potent agonist activity at both DA type 2 (D2R) and SST type 2 (SSTR2) receptors[1][2].
Related Catalog	Signaling Pathways >> GPCR/G Protein >> Somatostatin Receptor Signaling Pathways >> GPCR/G Protein >> Dopamine Receptor Signaling Pathways >> Neuronal Signaling >> Dopamine Receptor Research Areas >> Neurological Disease
References	[1]. Halem HA, et al. TBR-760, a Dopamine-Somatostatin Compound, Arrests Growth of Aggressive Nonfunctioning Pituitary Adenomas in Mice. Endocrinology. 2020 Aug 1;161(8):bqaa101. [2]. Cuny T, et al. Characterization of the ability of a, second-generation SST-DA chimeric molecule, TBR-065, to suppress GH secretion from human GH-secreting adenoma cells. Pituitary. 2021 Jun;24(3):351-358.

Description

Onzigolide (BIM-23A760), a chimeric dopamine-somatostatin compound, shows potent agonist activity at both DA type 2 (D2R) and SST type 2 (SSTR2) receptors[1][2].

Related Catalog

Signaling Pathways >> GPCR/G Protein >> Somatostatin Receptor

Signaling Pathways >> GPCR/G Protein >> Dopamine Receptor

Signaling Pathways >> Neuronal Signaling >> Dopamine Receptor

Research Areas >> Neurological Disease

References

[1]. Halem HA, et al. TBR-760, a Dopamine-Somatostatin Compound, Arrests Growth of Aggressive Nonfunctioning Pituitary Adenomas in Mice. Endocrinology. 2020 Aug 1;161(8):bqaa101.

[2]. Cuny T, et al. Characterization of the ability of a, second-generation SST-DA chimeric molecule, TBR-065, to suppress GH secretion from human GH-secreting adenoma cells. Pituitary. 2021 Jun;24(3):351-358.